We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Roche Diagnostics and Protedyne Sign Global Agreement

By Biotechdaily staff writers
Posted on 12 Feb 2007
Roche Diagnostics (Indianapolis, In, USA) and Protedyne (Windsor, CT, USA), a company offering industrial robotic solutions, are bringing together their latest technologies for the benefit of scientists worldwide. More...
In a collaborative effort, the two companies have integrated their technologies to provide a rapid and completely automated solution for high throughput quantitative polymerase chain reaction (PCR) applications.

Roche's LightCycler 480 instrument is a 96- or 384-well, plate-based quantitative PCR instrument. Combining speed with accuracy, the LightCycler 480 is a novel platform for gene-expression and mutation analysis. Based on innovative hardware and software, the LightCycler 480 instrument meets the needs of a broad range of genomic applications. The instrument builds upon the sensitivity and accuracy of the well-established LightCycler System, and now enables rapid high throughput quantitative PCR.

Protedyne's Radius is a new benchtop robotic system using the principles of industrial automation to offer high levels of flexibility, reproducibility, and process control for today's laboratories. Its radial design and vertical construction provide maximum functionality that can access areas of the bench top beyond its own footprint for simple and cost-effective device integration. The Radius system uses Protedyne's software that easily adapts to multiple protocols--and SmartTools, easily interchangeable tools with built-in microprocessors that store tool calibration information and track performance data.

Protedyne's Radius was a logical choice for the LightCycler 480 System as our technology provides the efficiency and throughput needed for highly- reproducible preparation across a broad range of scientific applications in genomics research, said Fran Tuttle, president and CEO of Protedyne. By combining the two systems, we can deliver to our customers exactly the throughput they are trying to achieve.



Related Links:
Roche Diagnostics
Protedyne

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Prefilled Tubes
Prefilled 5.0ml Tubes
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.